3D medical animation still shot showing the structure of a coronavirus. Credit: https://www.scientificanimations.com.

Canadian firm Arch Biopartners has secured approval to make certain protocol amendments to the Phase II trial of its lead drug LSALT peptide (Metablok).

The company announced that Health Canada, a government department, issued a No Objection Letter for the protocol amendments that were recommended by clinical investigators and key medical advisors associated with the study.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The international, multi-centre, randomised, double-blind, placebo-controlled, proof-of-concept study was designed to test the efficacy of LSALT peptide in preventing organ inflammation in severe cases of Covid-19.

Such inflammation often triggers acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI), leading to increased fatalities.

The protocol amendments were based on data procured from the first 45 patients enrolled for the Phase II trial.

The changes were intended to broaden patient eligibility, facilitate enrolment, execute a sixty-patient study, and improve patient care for those undergoing treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Health Canada has approved reducing the minimum age of patients admissible into the trial from 45 to 18. It also approved a simplified treatment regimen that reduces daily blood draws based on the safety profile observed in prior patients.

The two clinical sites currently active in Calgary, Canada, will adopt the changes following local internal review board approval.

The company will also submit the amended protocol to the US Food and Drug Administration (FDA) and the Turkish Ministry of Health to enable its adoption in the two countries.

Arch CEO Richard Muruve said: “We appreciate the rapid review and approval of the protocol amendment by Health Canada. The amended protocol will broaden the patient base and simplify our Phase II trial for Metablok.

“We look forward to the approval of the amendment by the respective ethic committees to make our trial more patient friendly, less labour intensive and more inclusive for a wider range of patients.”